200 related articles for article (PubMed ID: 37556125)
41. Patient Perspectives on Living With Severe Prurigo Nodularis.
Rodriguez D; Kwatra SG; Dias-Barbosa C; Zeng F; Jabbar Lopez ZK; Piketty C; Puelles J
JAMA Dermatol; 2023 Nov; 159(11):1205-1212. PubMed ID: 37728897
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
Igarashi A; Katsunuma T; Matsumura T; Komazaki H;
Br J Dermatol; 2023 Dec; 190(1):20-28. PubMed ID: 37522351
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
45. Molecular mechanisms of pruritus in prurigo nodularis.
Shao Y; Wang D; Zhu Y; Xiao Z; Jin T; Peng L; Shen Y; Tang H
Front Immunol; 2023; 14():1301817. PubMed ID: 38077377
[TBL] [Abstract][Full Text] [Related]
46. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
47. Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients.
Gao Z; Dou Y; Zhao P; Wang CJ; Zhang J
Dermatology; 2023; 239(4):658-663. PubMed ID: 37011607
[TBL] [Abstract][Full Text] [Related]
48. Clinical characteristics and disease burden in prurigo nodularis.
Aggarwal P; Choi J; Sutaria N; Roh YS; Wongvibulsin S; Williams KA; Huang AH; Boozalis E; Le T; Chavda R; Gabriel S; Kwatra SG
Clin Exp Dermatol; 2021 Oct; 46(7):1277-1284. PubMed ID: 33969517
[TBL] [Abstract][Full Text] [Related]
49. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
Zhang Z; Li S; Wang Y; Zhao J
An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
[TBL] [Abstract][Full Text] [Related]
50. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.
Janmohamed SR; Gwillim EC; Yousaf M; Patel KR; Silverberg JI
Arch Dermatol Res; 2021 Oct; 313(8):669-677. PubMed ID: 33108524
[TBL] [Abstract][Full Text] [Related]
51. Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.
Yook HJ; Lee JH
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791201
[TBL] [Abstract][Full Text] [Related]
52. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation.
Ständer S; Zeidler C; Pereira M; Szepietowski JC; McLeod L; Qin S; Williams N; Sciascia T; Augustin M
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):573-581. PubMed ID: 34908192
[TBL] [Abstract][Full Text] [Related]
53. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
Kabashima K; Furue M; Hanifin JM; Pulka G; Wollenberg A; Galus R; Etoh T; Mihara R; Nakano M; Ruzicka T
J Allergy Clin Immunol; 2018 Oct; 142(4):1121-1130.e7. PubMed ID: 29753033
[TBL] [Abstract][Full Text] [Related]
54. A randomized, double-blinded, vehicle-controlled clinical trial of topical cryosim-1, a synthetic TRPM8 agonist, in prurigo nodularis.
Choi ME; Lee JH; Jung CJ; Lee WJ; Won CH; Lee MW; Chang SE
J Cosmet Dermatol; 2024 Mar; 23(3):931-937. PubMed ID: 38169089
[TBL] [Abstract][Full Text] [Related]
55. Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study.
Taghaddos D; Savinova I; Abu-Hilal M
J Cutan Med Surg; 2024; 28(2):141-145. PubMed ID: 38281092
[TBL] [Abstract][Full Text] [Related]
56. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Kaneda N
Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
[TBL] [Abstract][Full Text] [Related]
57. Dupilumab as promising treatment for prurigo nodularis: current evidences.
Toffoli L; Farinazzo E; Zelin E; Agozzino M; Dianzani C; Di Meo N; Nan K; Zalaudek I; Conforti C
J Dermatolog Treat; 2022 May; 33(3):1306-1311. PubMed ID: 33588666
[TBL] [Abstract][Full Text] [Related]
58. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
59. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.
Murota H; Arima K; Yoshida T; Fujita H
J Dermatol; 2024 Feb; 51(2):223-233. PubMed ID: 38066728
[TBL] [Abstract][Full Text] [Related]
60. Dysregulation of the Skin-Liver Axis in Prurigo Nodularis: An Integrated Genomic, Transcriptomic, and Population-Based Analysis.
Marani M; Madan V; Le TK; Deng J; Lee KK; Ma EZ; Kwatra SG
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]